THIS IS THE BEST POST ON THE BOARD REGARDING ""BUY-OUT""
OTCShotCaller Monday, 08/30/21 01:44:40 AM
Re: None 0
of 98740 RGBP Buy Out Bidding WAR!
I strongly believe RGBP will be acquired between $5.75 to $6.25 per Share (i.e. $21.7 Billion to $23.6 Billion) in a "Bidding War" involving several Big Pharmas.
Here's the Short List of those Companies I previously identified:
#1 Gilead Sciences
#5 BioNTech https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165627226
It's important to recognize that based on Gilead's Sciences acquisition of Kite Pharma in 2017 it was based entirely on the mRNA Cancer Vaccine Patent Kite developed relative to its future global market potential when little was known about mRNA Biotechnology unlike today every Big Pharma in the Industry knows about it and is highly motivated to carve out a piece of that TRILLION DOLLAR MARKET in order to remain competitive in the rapidly advancing pharmaceutical landscape that's on the brink of radical transformation in medical therapeutics that will define the future of medicine! I have also previously discussed this at length.
It's things like this that catch most investors off guard like in the early days of Microsoft, Apple Computers, Amazon, etc., etc, when very little was known about these companies during their formative years when ALL of them were off everyone's radar!
Each one of them had one thing in common, they caused a fundamental shift in global society that re-defined the way people live. A complete transformation of society.
Kite Pharma did that via the Gilead Acquisition that brought the mRNA Vaccine Biotechnology front center stage to the Main Stream Pharmaceutical Industry and look where we are today with the mRNA Vaccine going GLOBAL to combat Covid-19.
This resulted in companies like Pfizer & Moderna mass producing and distributing the Covid Vaccine world wide that resulted in increasing their market revenues exponentially and protecting hundreds of millions of people from the effects of Covid-19.
The ONLY reason there was NOT a Big Pharma Bidding War over Kite Biopharma in 2017 was very little was known at that time about mRNA Bioscience that has to do with instructing cells in the human body to build immunity to the virus genome. The mRNA Vaccine "teaches" cells in the human body how to make proteins that triggers an immune response against an invading virus AND it is now known that it can protect against a variety of infectious diseases and even cancers. Very little of this was known back in 2017 but today is it is resoundingly clear!
The "take away"
RGBP has the same mRNA biotechnology in its Patent portfolio that today is already in the process of advancing into FDA Approved Clinical Trials via Oncology Pharma for treating pancreatic & colon cancer.
What few investors realize is the direction this is transitioning toward is the Immuno-Oncology Global Market along side many of the Major Big Phama players I previously identified on the link below: https://www.ventureradar.com/keyword/Cancer%20Vaccines
Each of RGBP's Patents are "advanced science based" and represent Disruptive Biotechnology. Each one is worth Billions and combined easily have a Trillion Dollar market capacity.
The mRNA Cancer Vaccine Market itself is a Trillion Dollar Market that the Big Pharmas listed on the above link are aggressively moving toward and so is RGBP!
With this said, it is a natural instinct of Big Pharmas to ACQUIRE cutting edge Biotechnology to expand their foot print in the Global Market which is what Gilead Sciences did in 2017 when they acquire Kite for nearly $12 Billion to obtain the only Patent Kite had at that time that was mRNA based for treating various cancers. The Kite scientists were on the cutting edge of this and look where we are today only 4 year later where many Big Pharmas are aggressively pursuing the Immuno-Oncology cancer vaccine prospect.
Based on this, and based on what is known TODAY about the Power of mRNA vaccine Biotechnology to modify immune transcription responses relative to viruses that is now extending to include its application for treating infectious diseases and cancers, it's just a matter of time before RGBP is bought out by a Big Pharma in order to fast track themself to carving out a portion of that global mRNA vaccine market sector and it will likely occur via a BIDDING WAR to ACQUIRE RGBP!!!
This would be consistent with the 8K Dr. Koos filed on 4/27/21 to prevent a Hostile Take Over by Big Pharmas seeking to ACQUIRE RBGP and it's very clear to me as a clinical trials physician based on what I know about the behavior & mentality of Big Pharmas, there's going to be an aggressive pursuit to acquire this company. WHY? Like I've said before....control of market share is what it's ALL about AT ANY COST and by any means necessary where MONEY is no obstacle!
This is the vicious and highly aggressive nature of the Big Pharma industry as a whole that I've previously discussed and unless you understand this, a Bidding War over RGBP won't make sense and I'm NOT saying it will definitely happen, but it is highly likely and if not then you have to ask yourself why did Dr. Koos file that 8K on 4/27/21?